Revenue Growth - Record net revenue of $114.6 million, a 23% increase year-over-year, driven by higher utilization and new accounts[2] - Sacral neuromodulation revenue reached $91.2 million, up 23% compared to the prior year period[2] - Bulkamid revenue grew to $23.4 million, a 25% increase year-over-year[2] - Net revenue for Q2 2024 increased to $114.565 million, up 23.3% from $92.894 million in Q2 2023[14] - Sacral neuromodulation revenue in the U.S. for Q2 2024 reached $89.076 million, up 23.4% from $72.205 million in Q2 2023[15] - Bulkamid revenue in the U.S. for Q2 2024 grew to $18.306 million, a 23.6% increase from $14.806 million in Q2 2023[15] Profitability and Margins - Gross margin expanded to 77.8%, up from 75.6% in the prior year period[2] - Gross profit for Q2 2024 rose to $89.143 million, a 27% increase from $70.190 million in Q2 2023[14] - Net income of $6.9 million, compared to a net loss of $7.3 million in the prior year period[2] - Net income for Q2 2024 improved to $6.899 million, compared to a net loss of $7.342 million in Q2 2023[14] - Comprehensive income for Q2 2024 was $7.365 million, a significant recovery from a comprehensive loss of $3.592 million in Q2 2023[14] Adjusted EBITDA - Adjusted EBITDA increased to $23.4 million, up from $18.4 million in the prior year period[2] - Adjusted EBITDA for Q2 2024 was $23.436 million, compared to $18.411 million in Q2 2023, reflecting a 27.3% increase[17] Cash and Assets - Cash, cash equivalents, short-term investments, and restricted cash totaled $362 million as of June 30, 2024[2] - Inventory increased to $105.4 million, up from $79.9 million in the prior year period[10] - Total current assets grew to $512.1 million, compared to $491.4 million in the prior year period[10] Liabilities - Total liabilities increased to $104.0 million, up from $82.4 million in the prior year period[11] Expenses - Research and development expenses for Q2 2024 increased to $12.792 million, up 42.9% from $8.949 million in Q2 2023[14] - Acquisition-related costs for Q2 2024 were $2.652 million, significantly higher than $602,000 in Q2 2023[14] - Stock-based compensation expense for Q2 2024 was $8.611 million, down from $11.204 million in Q2 2023[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Exhibit 99.1 Axonics Reports First Quarter 2024 Financial Results IRVINE, Calif. – April 30, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. "Our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year across our portfolio of incontine ...

Axonics, Inc. (AXNX) recently achieved a milestone with the CE Mark approval of its fourth-generation rechargeable Sacral Neuromodulation (SNM) system, the R20. This groundbreaking device is set to redefine the treatment landscape for bladder and bowel dysfunction, offering new hope to patients grappling with these challenging conditions.The R20 system is engineered for longevity and convenience, boasting a functional lifespan of at least 20 years within the body. This remarkable durability reduces the freq ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 116.67%. A quarter ago, it was expected that this medical technology company would post a loss of $0.05 per share when it actually produced earnings of $0.08, delivering a surprise of 260%.Over the ...

| --- | --- | |-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------| | Commission File Number: _________________________________________________________________ | 001-38721 | | Axonics, (Exact name of registrant as specified _________________________________________________________________ | Inc. in its charter) | | Delaware incorporation or organization) (State or other jurisd ...

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance. In fact, efficiency level, which measures a company’s capability to transform available input into output, is often considered an important parameter for gauging its potential to make profits.However, at times it becomes difficult to measure the efficiency level of a company. This is why one must consider popular efficiency ratios while selecting stocks.The ...

Shares of Axonics (AXNX 20.48%) were up 20.5% on Monday after the urology company agreed to be acquired by Boston Scientific (BSX 0.45%). Boston Scientific shares were also up around half a percent on the news today.A win-win deal for Axonics and Boston ScientificMore specifically, Axonics agreed to be acquired by Boston Scientific for $71 per share in cash, good for an equity value of $3.7 billion and (excluding Axonics' net cash and short-term investments) an enterprise value of $3.4 billion. Axonics shar ...

Financial Data and Key Metrics Changes - Axonics generated revenue of $93.1 million in Q3 2023, a 32% increase compared to the prior year period [6][15] - Sacral neuromodulation revenue was $73.9 million, up 30% year-over-year, despite a 42% growth comparison in Q3 of the previous year [6][15] - Bulkamid revenue reached $19.2 million, reflecting a 42% increase compared to the prior year [9][15] - Gross margin improved to 74.2%, up from 72.8% in Q3 of the previous year [9][15] - Adjusted EBITDA was $14 million, compared to $3.3 million in the prior year [17] Business Line Data and Key Metrics Changes - Sacral neuromodulation (SNM) revenue growth in the U.S. was driven by higher utilization and new competitive accounts [6][7] - Internationally, SNM system sales grew nearly 40% year-over-year, aided by a new direct sales force in Australia [8] - Bulkamid's growth was attributed to increased reorder rates and onboarding of new accounts [9] Market Data and Key Metrics Changes - Approximately half of SNM revenue growth in the U.S. came from existing customers increasing procedural volumes [6][7] - The DTC campaign generated over 10,000 qualified leads monthly, with over half of respondents being treatment naive [11][12] Company Strategy and Development Direction - The company aims to deepen relationships with existing accounts and enhance patient care pathways [22][25] - Axonics is focused on expanding its market share in the U.S. and internationally, particularly with the upcoming F15 product approval [8][14] - The company plans to continue its DTC advertising campaign and has launched new commercials targeting specific conditions [11][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 25% growth in SNM revenue year-over-year, with a market growth expectation of around 15% [28] - The company anticipates a gross margin of 74% to 75% for Q4 2023, with ongoing improvements expected [16][31] - Management highlighted the importance of the DTC campaign in driving awareness and revenue growth [12][68] Other Important Information - Axonics has approximately 415 commercial team members in the U.S., with a modest increase in headcount expected heading into 2024 [10][48] - The company is working on new product developments, including a foramen finder lead placement technology expected to be available in mid-2024 [14][52] Q&A Session Summary Question: What are the drivers of existing customer growth? - Management indicated that multiple initiatives, including symptom questionnaires and clinical specialist support, are driving growth in existing accounts [21][24] Question: What are the drivers to market leadership in the U.S.? - Management remains confident in achieving 25% growth in SNM revenue, with a focus on execution and market penetration [28] Question: Can you elaborate on margin expansion? - Management noted improvements in gross margin due to better production processes and supply chain management, with expectations for continued growth [31][32] Question: What is the outlook for international business? - Management emphasized the need for product approvals to enhance competitiveness internationally, particularly for the F15 product [37][39] Question: How does the DTC campaign impact demographics? - Management observed an increase in male inquiries through the DTC campaign, with plans to target specific conditions in upcoming commercials [66][68]